Biohaven Pharmaceutical (BHVN) Reaches New 12-Month High at $65.64

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $65.64 and last traded at $63.89, with a volume of 6329 shares trading hands. The stock had previously closed at $61.78.

Several equities research analysts recently commented on BHVN shares. Canaccord Genuity boosted their price objective on shares of Biohaven Pharmaceutical from $46.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Morgan Stanley lowered shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and set a $49.13 price objective on the stock. in a research note on Tuesday, April 9th. They noted that the move was a valuation call. Goldman Sachs Group started coverage on shares of Biohaven Pharmaceutical in a research note on Monday, May 6th. They set a “buy” rating and a $92.00 price objective on the stock. Needham & Company LLC boosted their price objective on shares of Biohaven Pharmaceutical to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, Piper Jaffray Companies boosted their price objective on shares of Biohaven Pharmaceutical from $75.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $69.91.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) EPS for the quarter, topping the consensus estimate of ($1.50) by $0.09. During the same quarter in the prior year, the business posted ($2.32) EPS. On average, equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.54 EPS for the current year.

In other news, Director Julia P. Gregory sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The shares were sold at an average price of $43.56, for a total value of $522,720.00. Following the transaction, the director now owns 12,000 shares in the company, valued at $522,720. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Declan Doogan sold 27,045 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $45.02, for a total transaction of $1,217,565.90. Following the completion of the transaction, the director now owns 394,083 shares in the company, valued at approximately $17,741,616.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 397,856 shares of company stock worth $20,507,075. Insiders own 23.90% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Biohaven Pharmaceutical by 19.5% in the first quarter. BlackRock Inc. now owns 2,858,893 shares of the company’s stock worth $147,149,000 after buying an additional 465,745 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Biohaven Pharmaceutical by 555.2% in the fourth quarter. Stifel Financial Corp now owns 2,719,538 shares of the company’s stock worth $100,569,000 after buying an additional 2,304,438 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Biohaven Pharmaceutical by 7.4% in the third quarter. JPMorgan Chase & Co. now owns 1,532,361 shares of the company’s stock worth $57,540,000 after buying an additional 105,913 shares in the last quarter. Samlyn Capital LLC lifted its stake in shares of Biohaven Pharmaceutical by 32.8% in the fourth quarter. Samlyn Capital LLC now owns 921,536 shares of the company’s stock worth $34,078,000 after buying an additional 227,432 shares in the last quarter. Finally, Foresite Capital Management IV LLC lifted its stake in shares of Biohaven Pharmaceutical by 0.6% in the fourth quarter. Foresite Capital Management IV LLC now owns 855,900 shares of the company’s stock worth $31,651,000 after buying an additional 4,700 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Biohaven Pharmaceutical (BHVN) Reaches New 12-Month High at $65.64” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/biohaven-pharmaceutical-bhvn-reaches-new-12-month-high-at-65-64.html.

Biohaven Pharmaceutical Company Profile (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: Why does a company issue an IPO?

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.